WuXi Biologics(2269.HK)
Focus: WuXi Biologics is a leading Contract Development and Manufacturing Organization (CDMO) headquartered in Wuxi, China, serving global biopharmaceutical companies with drug development and manufacturing services. The company operates at significant scale with 10,001–50,000 employees and is publicly traded on the Hong Kong Stock Exchange (ticker: 2269.HK).
Profile data last refreshed 3d ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Employees
10001-50000
Open Jobs
0
About WuXi Biologics
AI assessmentNot HiringNo open roles listed right now. Follow WuXi Biologics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Bevacizumab in Combination With Paclitaxel/Carboplatin
NSCLCRecent News · WuXi Biologics(10)
Help build intelligence for WuXi Biologics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.